// App-Quantinova.ai

e18238 : Pharmacoeconomic analysis of dalteparin vs. vitamin k antagonists (VKA) for the prevention of recurrent venous thromboembolism (VTE) in cancer patients with renal insufficiency.

Researchers

Presenter

  • George Dranitsaris

Principal Investigators

  • Lesley Shane

  • Seth Woodruff

  • Laura Burgers

Medical Centers

  • Augmentium Pharma Consulting Inc., Toronto, ON, Canada

  • Pfizer Inc, New York, NY

  • Pfizer Inc., Capelle a/d IJssel, Netherlands

Locations

  • United States

  • Canada

  • Netherlands

Companies

  • Augmentium Pharma Co

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Venous thrombosis

  • Renal insufficiency

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • dalteparin Subcutaneous

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved